Episodes

  • Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC

    Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC
    Jun 6 2025

    Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025
    Show more Show less
    37 mins
  • Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI

    Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI
    Jun 4 2025

    Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone
    Show more Show less
    20 mins
  • Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session

    Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session
    Jun 2 2025

    Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.
    Show more Show less
    30 mins
  • Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC

    Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC
    Jun 1 2025

    Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.

    Show more Show less
    31 mins
  • Episode 422: ACSO 2025 - ctDNA data from NIAGARA

    Episode 422: ACSO 2025 - ctDNA data from NIAGARA
    Jun 1 2025

    Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.
    Show more Show less
    33 mins
  • Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer

    Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer
    Jun 1 2025

    Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.
    Show more Show less
    35 mins
  • Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer

    Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer
    Jun 1 2025

    Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation
    Show more Show less
    24 mins
  • Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study

    Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study
    May 31 2025

    Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.
    Show more Show less
    24 mins
adbl_web_global_use_to_activate_T1_webcro805_stickypopup